The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

This is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority study (TATPITA20101005) to compare the efficacy and safety of pitavastatin (Livalo®) and atorvastatin (Lipitor®) in high risk hypercholesterolemic patients.

A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, Non-inferiority Study to Compare the Efficacy and Safety of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

20 Years to 75 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patient aged ≥ 20 years old and < 75 years old.

Patient who was eligible and able to participate in the study and accepts to enter the study by signing written informed consent.

Patient with fasting LDL-C > 100 mg/dL. The concentration of LDL-C is obtained from laboratory examination.

Patient with at least one of the following description (NCEP ATP III guideline).

Female patient with child-bearing potential must take reliable contraception method(s) during the participation of the study.

Exclusion Criteria:

Patient who has participated in other investigational studies within 3 months.

Patient took medication and natural health foods known to alter blood lipid profiles within 4 weeks.

Patient is taking any medication or food that is prohibited by the study.

Patient taking Amiodarone will be excluded from this study (due to long half life of this medication).

Patient is diagnosed with type 1 DM or has been using insulin/insulin analog medication.

Patient with a history of multiple drug allergies or with a known allergy to HMG-CoA reductase inhibitors.